Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01729559 · ClinicalTrials.gov registry record · Phase 4
Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin
A Phase 4 study, sponsored by Scripps Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 495
- Enrollment target
NCT01729559 is a Phase 4 study that has completed, run by Scripps Health. The registered enrollment target is 495 participants.
The verdict
NCT01729559, a Phase 4 study, has completed, sponsored by Scripps Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 495 participants
- Enrollment target
Study Summary
The rate of venous thromboembolic events in trauma patients at high risk for deep vein thrombosis and pulmonary embolism receiving low dose unfractionated heparin every 8 hours will be equivalent or less than a similar group of patients given a standard every 12 hour dose of low molecular weight heparin.
Interventions
- DRUG 5000 Units unfractionated Heparin Q 8 hr
- DRUG 30mg enoxaparin Q12 hr
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 495 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01729559
The ClinicalTrials.gov registry entry for NCT01729559 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 495 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scripps Health, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 5000 Units unfractionated Heparin Q 8 hr is the first listed.
NCT01729559 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01729559 about?
NCT01729559 is a clinical study titled "Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin". The rate of venous thromboembolic events in trauma patients at high risk for deep vein thrombosis and pulmonary embolism receiving low dose unfractionated heparin every 8 hours will be equivalent or less than a similar group of patients given a standard every 12 hour dose of low molecular weight hep...
What is the current status of trial NCT01729559?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 495 participants. The study started on 2012-11. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01729559?
The interventions under investigation include: 5000 Units unfractionated Heparin Q 8 hr (DRUG), 30mg enoxaparin Q12 hr (DRUG).
Who is sponsoring clinical trial NCT01729559?
This trial is sponsored by Scripps Health, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.